Press Releases

Newsroom
In the News
Press Releases
Resources for Journalists

Press Releases

Share
Share
and/or
506 News Releases found
CAR T Cells More Powerful When Built With CRISPR, MSK Researchers Find

MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don't tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.
Memorial Sloan Kettering Researchers Publish Roadmap to Precision Oncology

Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on a genetic understanding of a person’s cancer. Appearing in the special cancer-focused February 9 issue of <i>Cell</i>, the article — “Implementing Genome-Driven Oncology” — presents a critically self-reflective but solutions-focused perspective on this approach to cancer treatment.
Miami Cancer Institute Joins the Memorial Sloan Kettering Cancer Alliance

Today, after a yearlong review and collaborative process, Miami Cancer Institute at Baptist Health South Florida became a full member of the Memorial Sloan Kettering (MSK) Cancer Alliance. Miami Cancer Institute is the third member of the MSK Cancer Alliance, a transformative initiative that aims to improve the quality of care and outcomes for people with cancer in community settings.
Memorial Sloan Kettering and Hackensack Meridian Health Announce Cancer Care Partnership

Memorial Sloan Kettering and Hackensack Meridian Health announced the Memorial Sloan Kettering–Hackensack Meridian Health partnership, a joint venture that will combine both organizations’ unparalleled expertise in all areas of cancer care and research to accelerate new discoveries and improve the lives of patients they jointly serve.
Memorial Sloan Kettering Debuts in Monmouth County

Nearly 20 years have passed since Memorial Sloan Kettering Cancer Center (MSK) first opened its doors in the Garden State. Since then, an explosion of knowledge and data has resulted in far better outcomes for thousands of people with cancer, including many who’ve sought care at MSK’s facility in New Jersey.
MSK, The Rockefeller University and Weill Cornell Medicine announced that they have established a new drug discovery company called Bridge Medicines. This was launched in partnership with Takeda Pharmaceutical Company Ltd. Photo credit: Studio Brooke
Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.
Memorial Sloan Kettering Long Island Site Nearly Doubles

When Memorial Sloan Kettering Cancer Center (MSK) opened its doors along Commack Road in 2002, eastern Long Islanders no longer needed to navigate congested roadways and train lines bound for Manhattan to receive personalized cancer care. Today, more than 14 years later, MSK is reinforcing its commitment to the local community in the form of a 38,000-plus-square-foot addition complete with enhancements to both clinical programs and physical spaces.
Christine Mayr, MD, PhD
Molecular Biologist Christine Mayr of Sloan Kettering Institute Honored with Prestigious NIH Director’s Pioneer Award

Molecular biologist Christine Mayr, MD, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of 12 2016 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and supports individual scientists of exceptional creativity who propose pioneering and highly innovative approaches with the potential to produce an unusually high impact on biomedical or behavioral research.
Memorial Sloan Kettering Researchers Engineer “Micro-Pharmacies” in CAR T Cells to Treat B Cell Lymphomas

There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells. Historically, CAR T cell immunotherapy has aimed to boost the immune system by giving immune cells the information they need to better recognize tumor cells as foreign and attack them. New work led by Hans-Guido Wendel, MD, of Memorial Sloan Kettering Cancer Center (MSK), and collaborator Karin Tarte of the University of Rennes, France, illustrates an untapped potential of CAR T cells to act as targeted delivery vehicles that can function as “micro-pharmacies” for precise therapeutic delivery.
Memorial Sloan Kettering Launches MSK Direct to Expand Access to World-Class Cancer Care

In an effort to expand and streamline patient access to its high-quality cancer care, Memorial Sloan Kettering Cancer Center has introduced MSK Direct, a unique program in which MSK collaborates with external employers to simplify how their employees can engage with us for initial or ongoing cancer care.